Drug intelligence / Profile preview

SUVN-L3307032

Development stage: Preclinical
Lead developer: Suven Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

SUVN-L3307032 is a centrally acting small molecule that functions as a positive allosteric modulator (PAM) of the muscarinic M4 acetylcholine receptor. It enhances muscarinic M4 receptor signaling through an allosteric binding site, leading to modulation of dopaminergic tone in brain regions implicated in neuropsychiatric disorders. Preclinical studies demonstrated good oral bioavailability, excellent brain penetration, dose-dependent receptor occupancy, and efficacy in animal models of schizophrenia and psychosis. Preliminary toxicity data support its continued development for management of neuropsychiatric symptoms, including psychosis and agitation[2][5][7][9].

Other names: Muscarinic M4 receptor positive allosteric modulator

Targets

CHRM4 (M4)

Beyond the preview

Go deeper on SUVN-L3307032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUVN-L3307032.

Explore the full profile